HIGHLIGHTS
- who: Ying Cheng and Hongqi Tian from the Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine have published the research work: Current Development Status of MEK Inhibitors, in the Journal: (JOURNAL)
- what: The study showed that selumetinib had promising antitumor activity in children with low-grade glioma. A randomized phase III, open label, multicenter, two-arm study was designed to compare the efficacy of binimetinib versus dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanoma (NCT01763164). In vivo, the study showed that the combination of SL327 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.